NEW YORK (GenomeWeb) – As it presses ahead with Phase II development of its flagship hepatitis B therapy ARC-520, Arrowhead Research is banking on the drug's ability to cut levels of the virus's surface antigen (s-antigen), a key indicator of active infection, the company's top executive said this week.

According to Arrowhead President and CEO Chris Anzalone, treating HBV has proven especially challenging because blocking viral replication alone is not enough to clear the virus, unlike with hepatitis C.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.